You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Medtronic
Harvard Business School
McKinsey
Colorcon

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Liebel-flarsheim Company Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for LIEBEL-FLARSHEIM, and what generic and branded alternatives to LIEBEL-FLARSHEIM drugs are available?

LIEBEL-FLARSHEIM has eleven approved drugs.



Summary for Liebel-flarsheim
US Patents:0
Tradenames:14
Ingredients:5
NDAs:11

Drugs and US Patents for Liebel-flarsheim

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 DISCN Yes No   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 019710-005 Jan 22, 1992 RX Yes Yes   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 DISCN No No   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 019710-001 Dec 30, 1988 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Liebel-flarsheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 019710-002 Dec 30, 1988 4,396,598   Start Trial
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 020923-002 May 29, 1998 4,396,598   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 5,130,120   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-001 Dec 8, 1999 5,137,711   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.